Sleep Consortium is hosting this landmark initiative in collaboration with patient advocacy organizations that serve the IH community. Sleep Consortium has been approved by the U.S. Food and Drug Administration (FDA) to host to a patient-focused drug development (PFDD) meeting focused on IH. In addition, the initiative will also include a PFDD survey to ensure that this initiative reflects the experiences of as many people with IH as possible. A “voice of the patient” report will summarize the Illuminate Hypersomnia meeting and PFDD survey to serve as an enduring resource for researchers, drug development sponsors, regulators, healthcare professionals, and others. This initiative is also a way for members of the IH community to learn from and support one another.